In-vitro activity of 10 antifungal agents against 320 dermatophyte strains using micro dilution method in Tehran

Iranian Journal of Pharmaceutical Research

Volumn 12, Issue 3, 2013, Pages 537-545

  Adimi, Parvaneh ^a   Jamal Hashemi, Seyed ^a   Mahmoudi, Mahmood ^b   Mirhendi, Hossein ^a   Reza Shidfar, Mohammad ^a   Emmami, Masood ^a   Rezaei Matehkolaei, Ali ^c   Gramishoar, Mohsen ^a   Kordbacheh, Parivash ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; CICLOPIROXOLAMINE; CLOTRIMAZOLE; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; NAFTIFINE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTHRODERMA; ARTHRODERMA FULVUM; ARTHRODERMA GYPSEUM; ARTICLE; BROTH DILUTION; CONTROLLED STUDY; DERMATOMYCOSIS; DERMATOPHYTE; EPIDERMOPHYTON FLOCCOSUM; MICROSPORUM; MICROSPORUM CANIS; MICROSPORUM FERRUGINUM; MICROSPORUM RACEMOSUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TRICHOPHYTON CHOENLEINII; TRICHOPHYTON ERINACEI; TRICHOPHYTON ERIOTREPHON; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; TRICHOPHYTON TONSURANS; TRICHOPHYTON VERRUCOSUM; TRICHOPHYTON VIOLACEUM;

EID: 84883806466     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Erbagci Z. Deep dermatophytoses in association with atopy an diabet melitus:majocchi' s granuloma tricophytic dermatophytic pseudomycetoma. Mycopathologia. (2002) 154: 163-169.
2. Berg JC, Hamacher KL and Roberts GD. Pseudomycetoma caused by Microsporum canis in immunosuppressed patient: a case report and review literature. J. Cutan Pathol. (2007) 34: 431-434
3. Bueno, J.G., Martinez, C., Zapata, B., Sanclemente, G., Gallego, M. and Mesa, A.C. In-vitro activity of fuconazole, itraconazole, voriconazole and terbinafn against fungi causing onychomycosis. Clinical and Experimental Dermatology. (2010) 35: 658-663.
4. Ali SS, Zafar A., Muzaffar S, Aslam F and Khan JA. Bilateral breast enlargment due to Trichophyton rubrum. Breast. (2006) 15: 263-265.
5. Gong JQ, Liu XQ, Zeng XS and Li XF. Deep dermatophytosis caused by Trichophyton rubrum: report of two cases. Mycoses (2007) 50: 102-108.
6. Lillis JV, Dawson ES, Chang R and White CR. Disseminated dermal Trichophyton rubrum infection -an expression of dermatophyte dimophism? J. Cutan. Pathol. (2010) 37: 1168-1169.
7. Sarifakioglu E, Seckin D, Demirbilek M and Can F. In-vitro antifungal susceptibility pattern of dermatophyte strains causing tinea ungium. Clinical and Experimental Dermatology. (2007) 32: 675-679.
8. Nweze EI, Ogbonna CC and Okafor JI. In-vitro susceptibility testing of dermatophytes isolated from pediatric cases in Nigeria against five antifungals. Rev. Inst.Trop. S. Paulo,(2007) 49: 293-295
9. Ghannoum MA, Chatuverdi V, Espinel - Ingroff A, Pfaller MA, Rinaldi MG, Lee - Yang W and Warnock DW. Intra -and interl aboratory study of a method for testing the antifungal susceptibilities of dermatophytes. J. Clinical Microbiology (2004) 42: 2977-2979.
10. Favre B, Hofbauer B, Hildering KS and Ryder NS. Comparison of in-vitro activities of 17 antifungal drug against a panel of 20 dermatophytes by using a microdilution assay. J. Clinical Microbiolog. (2003) 41: 4817-4819.
11. Fernandez-Torres B, Carrillo - Munos AJ, Martin E, Del Palacio A, Moore MK, Valverede A, Serranno M and Guarro J. In-vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrobial Agents and Chemotherapy. (2001) 45: 2524-2528
12. Perea S, Fothergill AW, Sutton DA and Rinaldi MG. Comparison of in-vitro activities of voriconazole and fve established antifungal agents against different species of dermatophytes using a broth microdilution method. J. Clinical Microbiology (2001) 39: 385-388.
13. Fernandez -Torres B, Inza I and Guarro J. In-vitro activities of the new antifungal drug Eberconazole and three other topical agents against 200 strains of dermatophytes. J. Clinical Microbiology (2003) 41: 5209-5211.
14. nd ed., Clinical and Laboratory Standards Institute, wayne pa (2004).
15. Bueno JG, Martinez C and Zapata B. In-vitro activity of fuconazole,itraconazole,voriconazole and terbinafn against fungi as agent of onychomycosis. Clinical and Experimental Dermatology. (2010) 35: 658-663.
16. Carrillo-Munoz AJ, Giusiano G, Guarro J, Quindos G, Guardia C, Valle O, Rodriguez V, Estivill D and Cardenes CD. In-vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis. International J. Antimicrobial Agents. (2007) 30: 157-161.
17. Coelho L M, Ferreria RA, Leite Maffei CM and Martinez-Rossi NM. In-vitro antifungal drug susceptibilities of dermatophytes microconidia and arthroconidia. J. Antimicrobial Chemotherapy. (2008) 62: 758-761.
18. Ghannoum M, Skaggs B and Sheehan D. Voriconazle susceptibilities of dermatophyte Isolates obtained from a worldwide tinea capitis clinical trial. J. Clinical Microbiology. (2006) 44: 2579-2580
19. Falahati M, Omidi Tabrizi N and Jahaniani F. Anti dermatophyte activities of Eucalyptus camaldulensis in comparison with griseofulvin. Iranian J. Pharm. Therapeutics. (2005) 4: 80-83.
20. Shams-Ghahfarokhi M, Shokoohamiri MR, Amirrajab N, Moghadasi B, Ghajari A and Zeini F. In-vitro antifungal activities of Allium cepa,Allium sativum and ketoconazole against some pathogenic yeasts and dermatophytes. Fitoterapia. (2006) 77: 321-323.
21. Nowrozi H, Nazeri G, Adimi P, Bashashati Mand Emami M, Comparison of the activities of four antifungal agents in an in-vitro model of dermatophyte nail infection. Indian J. dermatology. (2008) 53: 125-128.
22. Pakshir K, Bahedinie L, Rezaei Z, Sodaif M and Zomorodian K. In-vitro activity of six antifungal drugs against clinically important dermatophytes. Jundishapur J. Microbiology. (2009) 2: 158-163.
23. Mikaeli A, Modaresi M, Karimi I, Fathi Mand Jalilian N. Antifungal activities of Astragalus verus oliver,against Trichophyton verruccosum on in-vitro and in-vivo guinea pig model of dermatophytosis. Mycoses.(2012) 55: 318-325.
24. Chadeganipour M, Nilippour S, Havaaei A, In-vitro evaluation of griseofulvin against clinical isolates of dermatophytes from isfahan. Mycoses. (2004) 47: 503-507.
25. nd ed., William and Wilkins, Baltimore,Maryland (1992) 45-46.
26. Li RY, Wan Z, Wang AP, Shen YN, Lu CM, Li M, Xi LY, Liu WD, Zeng FQ, In- vitro susceptibility testing of amorolfne in pathogenic fungi isolated from dermatomycosis patients in china. Mycoses. (2004) 47: 402-406.
27. Santos DA, Hamdan JS. In-vitro antifungal oral drug and drug - combination activity against onychomycosis causative dermatophytes. Medical mycology. (2006) 44: 357-362.
28. Galuppi R, Gambarara A, Bonoli C, Ostanello F and Tampieri MP. Antimycotic effectiveness against dermatophytes: comparison of two in-vitro tests.Vet Res Commun.(2010) 34: S57-S61.
29. Esteban A, Abarca ML and Cabanes FJ. Comparison of disk diffusion method and broth microdilution method for antifungal susceptibility testing of dermatophytes. Medical Mycology. (2005) 43: 61-66
30. Silva BARROS ME, Santos DA and Hamdan JS. In-vitro methods for antifungal susceptibility testing of Trichophyton spp. Mycological Research. (2006) 110: 1355-1360.
31. Gupta AK, Kohli Y. In-vitro susceptibility testing of ciclopirox, terbinafn, ketoconazole and itraconazole against dermatophytes and nondermatophytes,and invitro evaluation of combination antifungal activity. British J. Dermatology. (2003) 149: 296-305.
32. Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS and Ghannoum MA, Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafn. Antimicrobial Agents and Chemotherapy.(2003) 47: 82-86.
33. Korting HC, Ollert M and Abeck D. Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. Antimicrobial Agent And Chemotherapy. (1995) 39: 1206-1208.
34. Fernandez - Torres B, Inza I and Guarro J. Evaluation of disk diffusion method for determining eberconazole susceptibility of dermatophytes and infuence of culture medium. Antimicrobial Agents And Chemotherapy. (2005) 49: 2116-2118.
35. Mendez- Tovar LJ, Manzano- Gonzalez R, Velasquez-Hernandez V, Milan-Chiu B, Hernandez-Haernandaez F, Mondragon-Gonzalez R and Lopez-Martinez R. Resistance to azolic compounds in clinical Trichophyton spp. strains. Rev. Iberoam. Mycol. (2007) 24: 320-322.
36. Santos DA and Hamdan JS. In-vitro activities of four antifungal drugs against Trichophyton rubrum isolates exhibiting resistance to fuconazole. Mycoses. (2007) 50: 286-289.
37. Foroumadi A, Bolouri F, Moghami Tabrizi N, Davari Tanha F, Niroomand N, Azmoodeh A, Emami S and Falahati M. Effectiveness of fuconazole for suppressive maintenance therapy in patients with RVVC:a randomized placebo- controlled study. Iran. J. Pharm. Res. (2009) 8: 307-313.
38. Jafari-nodoushan AA, Kazemi AH, Mirzaii F and Dehghani M. Fluconazole susceptibility profle of candida isolates recovered from patients specimens admitted to Yazd Central Laboratory. Iran. J. Pharm. Res. (2008) 7: 69-75.